Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Based Tool Measures Cancer Aggressiveness

By LabMedica International staff writers
Posted on 17 Jul 2025

As cancer cases continue to rise globally, early diagnosis and precise treatment have become increasingly challenging. More...

Tumors, which are a leading cause of death, are becoming more complex, making it harder for researchers to predict their aggressiveness and resistance to treatment. The ability to assess how aggressive a tumor is and predict its behavior, including its likelihood to recur, is essential for improving treatment strategies. Now, a new artificial intelligence (AI) tool aims to address this challenge by predicting the aggressiveness of tumors through the identification of specific proteins. This tool, called PROTsi, measures a "stemness index," where a higher score indicates greater aggressiveness and resistance to drugs.

The machine learning model, developed by researchers from the University of São Paulo (São Paulo, Brazi), generates the stemness index based on protein expression data. To develop PROTsi, the researchers relied on datasets from the Clinical Proteomic Tumor Analysis Consortium (CPTAC), which includes data from 11 types of cancer, such as breast, ovarian, lung, kidney, and pancreatic cancers. The tool was designed to predict the aggressiveness of tumors by analyzing proteins linked to tumor progression and their similarity to pluripotent stem cells. As the disease progresses, the stemness index provides insight into how tumor cells are less differentiated, making them more likely to self-renew and become resistant to treatment.

PROTsi was validated across multiple data sets and shown to be effective in distinguishing between different levels of tumor aggressiveness. The research, published in Cell Genomics, confirmed that PROTsi could predict tumor aggressiveness and identify potential targets for new therapies. The tool demonstrated a better performance in differentiating higher-grade tumors, particularly in uterine, pancreatic, and pediatric brain cancers. While the tool works better for some cancers than others, it has the potential to be applied across a wide range of tumors. The researchers plan to continue refining the tool and testing additional computational models to improve predictions and clinical applications.

“We sought to build a model that can be applied to any cancer, but we found that it works better for some than for others. We’re making a data source available for future work,” said Professor Tathiane Malta from the University of São Paulo.

Related Links:
University of São Paulo


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Chemistry Control
Dropper Urine Chemistry Control
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.